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Summary 
Upon primary challenge with lymphocytic choriomeningitis virus (LCMV), H-2  a (BALB/cByJ) 
mice mount  a cytotoxic T  lymphocyte (CTL) response to a single immunodominant  domain 
of the viral nucleoprotein  (NP) but no detectable response to the viral glycoprotein (GP).  To 
manipulate  this CTL response,  the viral NP gene was expressed in the thymus and peripheral 
T  lymphocytes  using  the  murine  Thyl.2  promoter.  As  a  result,  such  Thyl.2-NP  (H-2  a) 
transgenic (tg) mice deleted their high-affinity anti-I_CMV-NP CTL, but generated equal numbers 
of lower-affinity NP CTL. Further, they made an alternative anti-LCMV-GP CTL response that 
is not normally found in non-tg mice indicating a hierarchial  control of the CTL response. Unlike 
the H-2  a mice, H-2  b (C57B1/6J) mice normally mount a CTL response to both LCMV-GP and 
-NP. When the LCMV-NP was expressed using the Thyl.2 promoter in these H-2  b mice, the 
LCMV-NP-specific CTL response was completely aborted and no CTL to new, alternative viral 
epitopes were generated.  Dilutions  of H-2  b or H-2  a NP peptides indicated  that  3-4 logs less 
H-2  b  NP  peptide  was  required  to  sensitize  syngeneic  target  cells  for  CTL-specific  lysis, 
suggesting  that  the  differing  affinities  of H-2  b and  H-2  a major  histocompatibility  complex 
molecules for their peptides likely account for the total removal of NP CTL in the H-2  b mice 
but only partial removal in H-2  a mice made to express thymic NP. Thymic grafting experiments 
done with thymi from newborn Thyl.2-NP  tg mice show that  selection processes studied in 
this model are of central (thymic) origin and are not caused by Thyl.2-positive LCMV-NP-expressing 
T  lymphocytes in the periphery. 
T 
he thymus plays a key role in the maturation and selec- 
tion process of T lymphocytes. Undifferentiated CD4 +  / 
CD8 + doubly positive precursor  cells  mature  into  CD4 + 
and CD8 + single positive cells (1). They acquire restriction 
for self-MHC through a process of positive selection, which 
is thought  to involve selection of those cells having TCRs 
with low but not zero affinity for complexes of self-peptide 
plus class II or I MHC molecules expressed on thymic epi- 
thelium  (2, 3).  In contrast,  thymocytes with  high  affinity 
for self-MHC (plus peptide) are deleted in a process termed 
negative selection (3-9). Similarly, expression of viral antigens 
in the thymus leads to deletion of virus-specific T cells during 
thymocyte maturation.  Although  this process is beneficial 
in removing anti-self (potential autoimmune) T  cells, it can 
also be harmful by providing a mechanism for viruses to per- 
sist over the life span of a host and cause chronic progressive 
disease (10-12). Furthermore, T cells with lower affinity can 
escape the negative selection process and emerge into the pe- 
riphery,  where they can cause autoimmune  disease (13). 
Virus-specific CTL are exquisitely specific in that they recog- 
nize  a  precise  viral  peptide  of 8-12  amino  acids  (aa) 1 in 
length presented by a unique MHC molecule. In H-2  d mice, 
>98% of the primary CTL response to lymphocytic chorio- 
meningitis virus (LCMV), whose genome encodes four pro- 
teins, focuses on only one viral determinant, the nucleoprotein 
(NP) aa 118-127. No detectable response to the viral glyco- 
protein (GP) is noted. H-2  b mice, in contrast,  make LCMV 
CTL to both, viral NP (aa 396-404) and GP (aa 33-41 and 
aa 276-286). We adapted this well-characterized situation to 
study the plasticity of the anti-LCMV CTL response (14-17). 
By using the Thyl.2 promoter (18, 19), we developed trans- 
genic mice (Thyl.2-NP tg mice) in which the viral NP gene 
was expressed in the thymus.  We then asked the following 
four questions. First, are all anti-LCMV-NP CTL deleted in 
1 Abbreviations used in thispaper: aa, amino acid; ARM, Armstrong; GP, 
glycoprotein;  LCMV, lymphocytic  choriomeningitis  virus; NP, 
nucleoprotein; tg, transgenic, w, vaccinia virus. 
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low-af~nity NP CTL still able to pass through  the thymus 
and populate peripheral lymphoid organs? Second, are CTL 
to new, alternative epitopes now generated? Third, if so, is 
the  altered  or newly generated anti-LCMV  CTL response 
sufficient to effectively control acute viral infection and pre- 
vent persistent infection? Fourth, can the same or a similar 
phenomenon be observed among several MHC haplotypes? 
The answers to these questions form the body of this report. 
Materials and Methods 
Generation of Tg Mice.  A vector utilizing the murine Thyl.2 
gene was  designed  to direct expression of viral  protein  to  the 
thymus (19, and see Fig.  1). The Thyl.2 promoter directs higher 
expression of the tg RNA to the thymus than peripheral T cells 
or fibroblasts (19). The complete cDNA for the LCMV-NP coding 
regions was  assembled  from overlapping cDNA clones derived 
from the small  (S)-R.NA  segment of LCMV-Armstrong (ARM) 
(16).  Correct orientation  and  sequence were confirmed by the 
Maxim Gilbert method (20). After cloning and amplification, the 
Thyl.2-LCMV-NP cassette was isolated, purified on a high-resolu- 
tion sucrose gradient, and used to generate tg mice as described 
(18). C57B1/6J (H-2  b)  x  BALB/cByJ (H-2  d) (b  x  d) mice were 
used as a source of oocytes, and injected eggs were implanted in 
pseudopregnant  CD1  females.  Founder mice demonstrating in- 
tegrated copies  of the transgene were crossed to b  x  d for one 
generation to confirm transmission of the transgene.  One line, 
Thyl.2-LCMV-NP 6-6, which had stably integrated and passed the 
LCMV-NP transgene, was  selected for detailed study. To obtain 
Thyl.2-NP mice with a H-2  a- or H-2b-restricted CTL response, 
b  x  d mice were bred to the fifth generation with BALB/cByJ 
or C57B1/6 mice. 
Biochemical Studies.  Mice carrying the transgene were identified 
by hybridization of DNA  extracted from tail biopsies  using an 
LCMV-NP-specific probe (20, 21). RNA to be analyzed was ex- 
tracted from their PBL and organs (thymus, brain, liver, and muscle) 
with the guanidinium-isothiocyanate method (20).  Before PCR. 
analysis  of LCMV-NP RNA,  RNA  samples  were treated with 
RNase-free RQ1 DNase to eliminate contaminating DNA. The 
RT-PCR was carried out as directed by the manufacturer (Perkin 
Elmer Cetus, Norwalk, CT) and PCR. was run for 40 cycles. LCMV- 
NP-specific primers were: 5' CAG TTA TAG GTG CTC TTC CGC 
3' and 5' AGA TCT GGG AGC CTT GCT TTG 3'. 
Virologic and Immunologic Studies.  Virus  stocks  consisted  of 
LCMV-ARM (clone 53b),  Pichinde virus, and vaccinia virus (vv) 
I_CMV GP and NP recombinants  that expressed LCMV-GP aa 1-398 
and LCMV-NP aa 1-558 (16, 21). Virus was plaque purified three 
times on Vero cells and virus stock prepared by a single passage 
on BHK-21 cells. Stocks of recombinant vv were prepared by infec- 
tion of 143 TK-  cells in media containing bromodeoxyuridine 
(22).  MC57  (H-2  b)  and  BALB/C17  (H-2  d)  cells  used  as  CTL 
targets were grown as reported (21). K2A cells stably transfected 
with L  d were generated as described (15). 
To determine CTL activity toward infected target cells, splenic 
CTL were obtained from mice 7 d after i.p.  inoculation of 2  x 
10  s PFU of LCMV (21). E/T ratios used were 100:1, 50:1, 25:1, 
12:1, and 6:1 for splenic CTL, and 10:1, 5:1, 2:1, and 1:1 for CTL 
clones.  Target  cells  (MC57/H-2 b,  BalbC17/H-2 d,  or  K2A/L  d) 
were infected with either LCMV or Pichinde virus for I h at 37~ 
(multiplicity of infection [MOI of 1]) or vv/LCMV recombinants 
for 1 h (MOI of 3). 48 (LCMWPichinde virus) of 12 h (w) after 
infection, cells were labeled with SlCr (21). Incubation of virus- 
infected or -uninfected 51CR-labeled targets with splenic CTL or 
CTL clones (21) lasted for 4.5-5 h, after which the amount of  chro- 
mium released was measured (21). LU were defined as the reciprocal 
of the number of effector cells required for 25% lysis of 104 targets 
determined by correlating several E/T ratios with the respective 
SXCr-release values. Killing of peptide-coated  uninfected target cells 
by CTL followed our reported procedures (23). 
To determine CTL activity after secondary stimulation, spleen 
cells harvested from mice 30-120 d after primary inoculation with 
10  s PFU LCMV i.p. were incubated with MHC-matched, irradi- 
ated, LCMV-infected macrophages in the presence of T cell growth 
factor and irradiated syngeneic spleen feeder cells (21). For precursor 
frequency analysis, spleen cells were harvested on day 7 after pri- 
mary LCMV infection. These cells were diluted serially and culti- 
vated in 96-well flat bottom plates in the presence of T cell growth 
factor  and  syngeneic  irradiated  LCMV-infected  (103 PFU/ml) 
spleen cells (10Vwell).  After 9 d, each well was assayed for CTL 
lysis (described  above) on target cells that were uninfected or in- 
fected with LCMV or vv and that expressed NP or GP. The frac- 
tion of positive cultures (lysis > 11%) was determined for each di- 
lution. 
The phenotype of surface molecules expressed on lymphocytes 
was  tested by incubating cells with mAbs to murine CD4 (rat 
mAb YTS 191.1.1), CD8 (rat mAb YTS 169.4.2),  or Thyl.2 for 
30 min followed by incubation with mouse anti-rat Ig FITC re- 
agent (21) and quantitation or sorting by FACS  |  (Becton Dick- 
inson & Co., Mountain View, CA) (21). LCMV-specific antibody 
was determined by a solid-phase  ELISA (21, 24, 25).  Antibodies 
to  LCMV-NP  in  the  sera  of  tg  mice  were  defined  using 
[3SS]methionine-labeled LCMV-infected BHK cells, immune pre- 
cipitation, and SDS-PAGE  (21). 
Thymic Transplantations.  To isolate and observe the function of 
the thymus in our tg mice, we anesthetized SCID mice with ket- 
amine and Metophane (Pitman-Moore, Mundelein, IL), and thymi 
excised from 1-d-old newborn tg or non-tg pups were implanted 
under their renal capsules using sterile conditions. Thymi were al- 
lowed to develop for 6 wk and then experimentally assayed for their 
ability to generate LCMV-specific CTL activity. 
Immunohistochemical  Studies.  Pancreata and spleens were removed 
and quick-frozen in O.C.T. compound, after which 6-10/zm sec- 
tions were cut, mounted on sialin-coated superfrost plus glass slides 
(Fisher Scientific, Pittsburgh, PA), fixed,  and stained  as reported 
(13). Primary antibodies were rat anti-mouse L3T4, rat anti-mouse 
Ly2 and Ly3 (Pharmingen, Sorrento Valley, CA), and secondary 
antibody was biotinylated goat anti-rat IgG (Boehringer Mann- 
heim, La Jolla, CA).  Hematoxylin-eosin stains were carried out 
on paraf~n-mounted tissue  fixed with Bouin's fixative. 
Results 
LCMV-NP RNA Is Expressed in Thymus, Spleen, Brain, and 
PBL ofThyl.2-NP tg Mice.  When tested by PCR, LCMV- 
NP RNA  (289-bp  fragment)  was  expressed in  the  spleen, 
thymus, Thyl.2-positive PBL (FACS|  twice) and brain 
of Thyl.2-NP tg mice (Fig. 2). However, no LCMV-NP RNA 
was found in Thyl.2-negative PBL or in pancreas,  kidney, 
muscle, or liver from Thyl.2-NP tg mice. Despite several at- 
tempts using immunohistochemical  staining techniques on 
tissues, we were unable to detect LCMV-NP protein in the 
thymus.  As reported elsewhere (21),  this  is due to the in- 
ability of the antibody to detect low expression of NP trans- 
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Figure 1.  Construction  of the cassette for generation of Thyl.2 NP 
tg mice. Within the murine Thyl.2 gene (a), exon 2 (E2) was replaced 
by a synthetic exon 2. Two 54-mer oligos (b) were synthesized, recon- 
structing the splice  donor (SD) and splice acceptor (SA) sites and creating 
a unique BgllI cloning site. The synthetic exon was inserted in place of 
the original E2 at the Clal site between exons Elb and E3 (c). The BgllI 
site was now used to insert the full-length LCMV-NP cDNA (d) into the 
synthetic exon 2 of the Thyl.2 gene. The cloning vector used for these 
constructs was pUC13. The final cassette used for generation of tg mice 
was the EcoRI fragment containing all exons of the Thyl.2 gene and the 
LCMV cDNA,  as shown in e. 
gene protein.  Such low levels of NP protein can be detected 
by MHC-restricted,  NP-specific  CTL  (21). 
CTL Response to LCMV-NP Is Aborted in 1-1-2  b Thyl.2-NP 
tg Mice.  The LCMV-specific CTL response was measured 
in H-2  b Thyl.2-NP tg mice and their non-tg littermates 7 d 
after challenge with 10  s PFU of LCMV i.p. As expected (21) 
and as shown in Table 1, CTL from non-tg C57BL/6  (H-2  b) 
and non-tg  C57B1/6  x  BALB/c (b  x  d) mice killed both 
LCMV-GP- and -NP-expressing MHC-matched target cells, 
whereas CTL from BALB (H-2  a) mice killed only I.CMV- 
NP-expressing  syngeneic targets,  but  not  those  expressing 
LCMV-GP.  In  contrast,  CTL  from  H-2  b  ThyL2-NP  tg 
mice failed to kill LCMV-NP-expressing  syngeneic targets, 
but did lyse those expressing LCMV-GP.  Thus,  the LCMV- 
NP-specific CTL response was specifically aborted in H-2  b 
Thyl.2-NP  tg  mice. 
CTL  Response to LCMV-NP in 1-1-2  a Thyl.2-NP  tg Mice 
Is Markedly  Reduced but Not Aborted.  In non-tg H-2  d mice, 
the primary CTL response was to viral NP with no response 
to GP  (Table  1).  As  seen in  Fig.  3  (A),  unlike  H-2  b mice, 
H-2  d Thyl.2-NP  mice  still  generated  a  CTL  response  to 
LCMV-NP  but  of considerably lower activity than  that  of 
their  age- and  sex-matched non-tg littermates.  This reduc- 
tion  of the  CTL response was  specific for LCMV,  because 
tg  and  non-tg  H-2  a mice  made  equivalent  CTL  responses 
to both Pichinde and vaccinia viruses (Table 2). Hence, thymic 
expression  of the  I.CMV-NP  transgene  dampens  the  anti- 
LCMV-NP CTL response specifically, but not CTL responses 
against  other  viruses. 
We then assessed the numbers and characteristics of these 
CTL with lower activity. As shown in Fig. 4 B,  10-fold-less 
antibody to CD8 was required  for a 50%  reduction  of lysis 
by NP-specific CTL from ThyL2-NP tg mice than from non- 
tg controls. Fig. 4 A  documents that 10-fold-greater amounts 
of  the  immunodominant  NP  peptide  (RPQASGVYMG) 
(50%  end  point  lysis)  was required  to coat  target  cells for 
lysis by LCMV-NP-specific CTL from the tg than from the 
non-tg mice. Finally, Fig. 3 B shows that the number of CTL 
precursors for low-activity CTL in Thyl.2-NP  tg mice vir- 
tually equaled  those for high-activity CTL in their  non-tg 
littermates.  These data  show  that  for H-2  a Thyl.2-NP  tg 
mice, the reduced  activity of CTL results from their lower 
affinity for LCMV-infected target cells and not from an overall 
reduction  in  numbers  of CTL. 
Less LMCV-NP Peptide Is Required  to Sensitize  1-1-2  b than 
Figure 2.  Detection of LCMV- 
NP KNA in thymus, spleen, brain, 
and Thyl.2-positive PBL but not in 
pancreas or Thyl.2-negative  lym- 
phocytes of Thyl.2-NP  tg  mice. 
KNA samples were obtained from 
organs  of  ThyL2-NP  tg  mice. 
Splenic RNA from a mouse persis- 
tently  infected with  LCMV  and 
containing viral RNA sequences in 
its spleen served as a positive con- 
trol. All samples  were treated with 
KNase-free  KQ1  DNase  before 
starting  the  reverse transcriptase 
reaction to remove traces of con- 
taminating DNA. Negative control 
lanes without  addition  of reverse 
transcfiptase  do  not  show any 
l_CMV-NP-specific  product. Treat- 
ment of KNA with lkQ1 DNase 
does not affect  the amount of PCR 
product (first two lanes with con- 
trol RNA on the left side of the 
graph). 
1903  yon Herrath  et al. Table  1.  Thy  1.2 NP (H-2  b) Tg Mice Fail to Generate LCMV-specific CTL to Viral NP but Generate CTL to Viral CP 
Percent  specific StCr released  from targets infected with: 
H_2  b  H-2  d 
Day 7 primary  H-2 
splenic  CTL from:  type  ARM  vvNP  vvGP  ARM  vvNP  vvGP 
Non-tg mice: 
C57/B16  b  46  +  8  18  _+  3  24  _+  2  0  2  _+  1  2  +  2 
BALB/c  d  0  0  1  _+  1  64  +_- 9  30_+  7  6_+  2 
C57/B16  x  BALB  b  x  d  54  _+  7  25  +  3  31  -+  5  61  +  10  36_+  8  2_+  2 
Thy 1.2  NP tg mice: 
No.  38  b  24  2  17  7  4  5 
No.  40  b  40  5  22  4  2  5 
No.  41  b  43  2  23  6  1  5 
6-8-wk-old Thyl.2 NP mice and non-tg littermates received 10  s PFU i.p. of LCMV-ARM (clone 53b). 7 d later, lymphocytes were harvested from 
spleens and assayed for MHC-restricted LCMV-specific  CTL activity. Effectors used at a ratio of 50:1 are shown. 51Cr-labeled target cells were H-2b 
(MC57) or H-2  a (BALB/C17) fibroblasts uninfected or infected with LCMV-ARM or vaccinia recombinants expressing LCMV-NP (vvNP) or LCMV- 
GP (vvGP). Variance was <10% in three separate experiments. Mean value _+  1 SD is shown for groups of 20 non-tg mice. The three tg mice 
represent equivalent data for >10 mice studied. 
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Figure  3.  (A) Analysis of LCMV-NP-specific CTL generated in the 
spleens of non-tg H-2  d control (e) or Thyl.2-NP H-2  a tg (O) mice. Bar 
represents 2 SE for each time point. Targets were SlCr-labeled BALB/C17 
(H-2  d) fibroblasts infected with vv/LCMV NP recombinant. H-2 restric- 
tion occurred, as killing of similarly infected H-2  b targets did not cause 
slCr release. Four to five mice were used per group. See Materials and 
Methods section for CTL assay. (B) Numbers of CTL precursors in Thyl.2- 
NP tg mice and non-tg littermates. Analysis  was performed as described 
in Materials and Methods. Positive  cultures showed  a specific  lysis of> 11%. 
Activity of CTL from Thyl.2-NP tg mice on LCMV-infected  targets (O) 
1-1-2  a Targets for Lysis  by  CTL.  The  optimal  LCMV-NP 
peptide  for  recognition  by  CTL  of  H-2  b  mice  is 
FQPQNGQFI  (NP  aa  396-404)  and  for  H-2  d  mice  is 
RPQASGVYMG (NP aa  118-127).  As shown in Fig.  5,  at 
10-13 M  peptide FQPQNGQFI still sensitized H-2  b targets 
(Gairin, J.E., A. Tishon, and M.B.A. Oldstone, manuscript 
submitted  for publication)  for lysis  by Db-restricted  anti- 
LCMV CTL.  In contrast,  10-9 M  peptide (or 4 log more) 
was required to sensitize H-2  d targets for Ld-restricted anti- 
LCMV CTL lysis. 
The anti-LCMV Immune Response of Thyl.2-NP tg Mice Is 
Equivalent to that of Non-tg Littermates.  Next, we questioned 
whether Thyl.2-NP tg mice cleared an acute LCMV infec- 
tion as well as had their non-tg littermates. As Table 3 shows, 
by 3 wk after infection, the virus was completely cleared from 
serum,  brain,  lung,  and liver as well as from PBL,  spleen, 
central nervous system, and muscle (data not shown) in both 
groups of mice. By contrast, mice depleted of CD8 cells ge- 
netically  (32-microglobulin  knockout  mice)  or  immuno- 
chemically (mice given antibody to CD8) failed to clear virus 
from sera or tissues  (Table 3). 
Non-tg mice inoculated with as little as 10 PFU of LCMV 
intracerebrally (i.c.) died of acute leptom~ningitis within 10 d. 
Death resulted from the activity of LCMV-specific NP CTL 
in H-2  d mice as shown by depletion of CD8 cells and recon- 
and targets expressing LCMV-GP ([-]). BALB/c  mice LCMV targets (O) 
and targets expressing LCMV-GP (11). Average  lysis found for BALB/c 
cultures was 22 _+ 4%, for Thyl.2-NP cultures 11 -  2% on LCMV targets 
and 23  +  4% on GP-expressing targets. 
1904  Thymic Selection and Adaptability of CTL Responses Table  2.  LCMV-NP (H-22) Tg Mice Make Normal CTL Responses to Pickinde and Vaccinia Virus but a Reduced Response to LCMV 
LU of virus-infected cells 
Virus  Day  7  primary  spleen  H-2 
innoculated  CTL  obtained from  type  H-2d  H-2b 
Pichinde  BALB/c  d  32  _+  -  4  0 
Pichinde  C57B1/6  b  0.2  22  _+  -  2 
Pichinde  Thyl.2  NP  d  39  _+  -  2  0.3 
Vaccinia  BALB/c  d  23  _+  -  4  0.1 
Vaccinia  C57B1/6  b  0  17  _+  -  1 
Vaccinia  Thyl.2  NP  d  33  _+  -  5  0.3 
LCMV  BALB/c  d  25  _+  -8  0 
LCMV  C57B1/6  b  0.2  22  _+  -4 
LCMV  Thyl.2  NP  d  4  _+  -2  0 
6-8-wk-old Thyl.2 NP tg mice (bred to Fs  on Balb/H-2  a background) or non-tg mice were inoculated with Pichinde, vaccinia,  or LCM virus. 
slCr-labeled target cells were H-2  b (MC57)  and H-2  d (BALB/C17) fibroblasts uninfected or infected with Pichinde,  vaccinia, or LCM viruses. Procedure 
for determination of LU from slCr release is given in the Materials  and Methods. Numbers represent mean values  _+  1 SE from four mice per group. 
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Fig.re  4.  (A)  Thyl.2-NP  H-2  a  tg  mice  (O)  generate LCMu 
NP-specific CTL with less a~nity than NP-specific CTL made by age- 
and sex-matched  non-tg controls (e). The NP sequence for which H-2a 
CTL are restricted is RPQASGVYMG. Differing concentrations of this 
peptide were used to coat SlCr-labeled H-2  d BALB/C17 fibroblasts,  and 
the mixture was incubated with CTL and E/T ratios of 50:1  and 25:1 
with data from 50:1 shown. Coating of H-2  b slCr-labeled targets with 
this peptide did not result in cell lysis. Bar indicates 2 SE for four to five 
mice used per each group.  See Materials  and Methods for slCr-release 
assay. (B) Less antibody to CD8 (monoclonal GK1.5) is required to inacti- 
vate CD8 + LCMV NP-specific CTL obtained from Thyl.2-NP H-2  d mice 
(O), than from age- and sex-matched non-tg controls (e). Bar indicates 
2 SE. Four to five mice were used per group, mAb to CD8 at different 
dilutions was incubated with the CD8 + effector cells. E/T ratios used 
were 50:1  and 25:1  with data from 50:1  shown. 
stitution with La-restricted CTL clones that recognize NP 
aa 118-127 (26). After i.c. inoculation orS0 PFU LCMV into 
Thyl.2-NP mice (H-2  d or H-2b), non-tg H-2  b or H-2  a con- 
trols,  all mice (8-10 per group) died from leptomeningitis 
7 -10 d after challenge.  Mice depleted of CD8 cells did not 
die but became persistently infected. 
When antibody to LCMV and LCMV-NP was measured 
by ELISA and Western blot (21) in tg and non-tg H-2  d mice 
3  wk  after  i.p.  challenge  with  10  s PFU  of LCMV,  titers 
were equivalent in both groups. Similarly,  the overall number 
of CD4 and CD8 cells in peripheral  blood and spleens  of 
the Thyl.2-NP mice was equivalent to that in non-tg con- 
trols (four mice/group) as determined by FACS  |  analysis  at 
3, 7,  14, and 30 d after LCMV infection (data not shown). 
Thyl.2-NP 1"1-2  J Mice Generate New CTL to an Alternative 
LCMV-GP  Epitope.  CTL  generated  by  H-2 a  Thyl.2-NP 
mice displayed roughly threefold less specific activity toward 
LCMV (whole virus) and LCMV-NP than did nonotg age- 
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o  ~  so 
~,  ￿9  40 
w  30 
~.n.  20 
10 
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i  i  i  i  i  i  i  i  i  i  i 
16  -15  -14  -13  -12  -11  -10  -9  -8  -7  -6  -5 
Peptide (-log M) 
Figure  5.  Amount of H-2  b restricted NP peptide FQPQNGQFI  (aa 
396-404) and H-2d-restricted NP peptide RPQASGVYMG (aa 118-127) 
required to coat appropriate H-2  a or H-2  b targets for lysis. See legend to 
Fig.  3 A. 
1905  von Herrath et al. Table  3.  Acute LCMV Infection Is Cleared by 1-1-2  a Thyl.2 NP Tg Mice as Efficiently as by Non-Tg Mice 
PFU/ml serum  PFU/g tissue  day 21 
Host  (10 mice/group)  Day 7  Day 14  Day 21  Brain  Liver  Lung 
Non-tg  7  x  103  0  0  0  0  0 
immunocompetent 
Non-tg CD8  1  x  10  4s  1  x  103  1  x  10  s2  1  x  104-s  1  x  10  4.6  ND 
depleted 
Tg Thyl.2 NP  7  x  103  0  0  0  0  0 
Clearance of LCMV in Thyl.2 NP mice. Mice were infected with 2  x  10  s PFU i.p.  LCMV and viral titers (PFU/ml  or PFU/g)  assessed 7, 14, 
or 21 d later in serum and selected tissues (brain, lung,  and liver) by plaque assay (see Materials and Methods). 
and sex-matched controls (Fig. 3 A). Nevertheless, Thyl.2- 
NP  tg  mice  cleared  virus  with  the  same  kinetics  and  as 
efficiently as non-tg littermates. Further, both groups showed 
similar kinetics  and outcome of CTL-mediated lethal cho- 
riomeningitis after i.c. inoculation of virus. To further evaluate 
this issue, we measured the virus-specific CTL response over 
the course of infection.  Table 4  shows  that  for as  long as 
60-120 d  after infection,  Thyl.2-NP H-2  d mice continued 
to generate low-activity LCMV-NP-specific CTL. However, 
unlike the non-tg controls, the tg mice produced a new anti- 
LCMV-GP CTL response  (Table 4).  Precursor  frequencies 
were, however, 50-100-fold lower than those found for low- 
activity NP CTL (Fig. 3 B). Therefore, GP-specific CTL ac- 
tivity  could  be  measured  only  after  secondary  in  vitro 
amplification of CTL. Using several vv/LCMV GP minigene 
recombinants  (14,  15,  17,  22,  23),  the H-2d-restricted epi- 
tope was mapped between  aa  1 and  171  of LCMV-GP. 
Lymphocytes Developing fiom the Thymus of H-2  d Thyl.2-NP 
tg Mice Exhibit lower CTL Activity than those  fiom non-tg Lit- 
termates.  Final  studies  evaluated  the development  of lym- 
phocytes  from  thymi  obtained  from  Thyl.2-NP  H-2  dtg 
mice  and  transplanted  under  the  renal  capsules  of H-2  a 
Table  4.  Generation of a Novel CTL Response to LCMV-GP in 1-1-2  a Thyl.2-NP  Tg Mice 
CTL cultures  tested 
Secondary CTL 
obtained from: 
Percent  specific SlCr released  from targets infected  with: 
H-2  a  H-2  b  Ld 
H-2  Wk after LCMV  E/T 
type  inoculation  ratio  ARM  vvGP  vvNP  ARM  vvGP  vvNP  vvGP 
Non-tg 
Thyl.2 NP 
tg 
Non-tg 
Thyl.2  NP 
tg 
d  8  5:1  81  6  71  4  1  0  1 
d  4  10:1  48  25  35  3  2  1  ND 
5:1  38  20  23  ND  ND  ND  ND 
2:1  27  17  ND  ND  ND  ND  ND 
6  5:1  47  22  22  2  1  0  14 
10  10:1  60  24  25  5  3  2  6 
5:1  46  19  19  ND  ND  ND  ND 
2:1  32  15  0  ND  ND  ND  ND 
b  8  5:1  3  1  0  51  36  16  ND 
b  6  5:1  2  1  0  48  24  2  ND 
10  10:1  1  3  4  56  34  1  ND 
5:1  1  2  1  54  28  2  ND 
6-8-wk-old Thyl.2-NP H-2  d tg and non-tg mice were inoculated with  1-2  x  10  s PFU LCMV i.p.  At 4-10 wk after inoculation, spleens were 
harvested and placed in culture with syngeneic, irradiated, and LCMV-infected macrophages (see Materials and Methods). After 2 wks in culture, 
lymphocytes were harvested and tested in a 5-6-h SlCr-release assay against syngeneic or allogeneic target cells that were uninfected or infected with 
LCMV or vaccinia reeombinants expressing LCMV-NP or LCMV-GP. An Ld-expressing target cell line was also used (K2A fibroblasts). Numbers 
represent the mean of triplicate samples with  variance <10%. Similar results were obtained in three other experiments (three mice per group). 
1906  Thymic Selection and Adaptability of CTL Responses Figure 6.  Immunohistochemical  study to detect  CD4 and CD8 bearing lymphocytes  in normal spleen as compared  to those  in thymus  and spleen 
7 wk after renal capsule grafting  of Thyl.2-NP (H-2  d) newborn thymi into SCID mice. Panels show the following  tissue stained with: (la) normal 
spleen, hematoxylin;  (2a) normal  spleen, CD4 stain and hematoxylin;  (3a) normal  spleen, CD8 stain, and hematoxylin;  (lb) SCID kidney  and capsule 
after grafting  of Thyl.2-NP thymus,  hematoxylin-eosin;  (2b) SCID kidney  and capsule after  grafting  of Thyl.2-NP thymus,  CD4, and hematoxylin; 
(3b) SCID kidney  and capsule after  grafting  of Thyl.2-NP thymus,  CD8 stain, and hematoxylin;  (lc) SCID spleen and hematoxylin;  (2c) SCID spleen 
after grafting  of  Thyl.2-NP  thymus,  CD8 stain, and hematoxylin;  and (3c) SCID thymus  after  grafting  of Thyl.2-NP  thymus,  CD8 stain, and hematoxylin. 
C.B.17/scid/scid  (SCID) mice. 6-7 wk after transplantation 
of thymi or fat tissue (negative control) from Thyl.2-NP mice 
or of thymi from non-tg littermates (positive control), SCID 
mice received  105  PFU i.p.  of LCMV,  and 7 d  later their 
spleens were removed and analyzed for anti-LCMV and anti- 
LCMV-NP CTL activity. Fig. 6 demonstrates (a) the local- 
ization of CD4 and CD8 lymphocytes in a normal spleen; 
(b)  the thymic transplant under the renal capsule  of SCID 
mice; and (c) CD4 and CD8 lymphocytes in the spleen and 
thymus of a SCID mouse after transplant. As seen in Fig. 
6, transplanted thymic lymphoid cells migrated from under 
the renal capsule into lymphoid organs. Neither CD4 nor 
CD8 lymphocytes  were detected in any SCID mouse without 
a thymic transplant, and kidneys of the SCID mice did not 
show GVHD. As shown in Table 5, CTL killing of LCMV- 
or LCMV-NP-expressing target cells was reduced two- to 
threefold in SCID recipients of the Thyl.2 NP H-2  a trans- 
plants compared to SCID mice receiving thymi from BALB/c 
mice or from non-tg littermates. 
Discussion 
Tg mice were used as a model to study the impact of a 
viral gene expressed in the thymus upon subsequent genera- 
tion of the CTL response to the same virus. To develop this 
model, one viral gene of LCMV, the NP, was expressed in 
tg mice using the murine Thyl.2 promoter. This allowed 
us to determine whether negative selection of CTL was total 
or partial and to study whether new CTL responses to "un- 
expected" epitopes were generated once the NP CTL response 
had been disrupted.  Our data show that in H-2  b tg mice, 
the CTL response to LCMV-NP is completely aborted. By 
contrast,  in  H-2  d tg  mice  the  immunodominant NP  re- 
sponse is diminished but not aborted. These findings are in- 
versely associated with the affinity  between MHC/viral (NP) 
peptide and CTL. 10,000-fold  fewer H-2  b NP peptide mol- 
ecules  (dilution end point  10-13 M) were needed to sensi- 
tize H-2  b targets  for  CTL killing than H-2  a NP  peptide 
(10 -9 M). In addition, H-2  d tg mice generated a new CTL 
response to LCMV-GP, which mapped between aa 1 and 171. 
1907  von Herrath et al. Table  5.  CTL Activity Developed  from Thymi of Thyl.2 NP Tg Mice Transplanted into SCID Mice 
Experimental group 
CTL response 
Percent specific SlCr-release from 
target cells infected with: 
H.2  d  H-2  b 
Thymus  Thymus  No. 
donor (H-2  d)  recipient (H-2  a)  of mice  LCMV-ARM  vvNP  LCMV-ARM 
BALB/c  SCID  2  50-+  -8  28  -+  -7  2  -+  -1 
Nonexpressor:  SCID  4  45  _+  -  12  22  _+  - 5  3  _+  - 2 
Thyl.2 NP 
Expressor:  SCID  6  20  _+  -8  10  _+  -9  2 _+  -1 
Thyl.2 NP 
Fat tissue  SCID  4  2  _+  -4  3  _+  -1  4_+  -2 
Thymi were obtained from Thyl.2 NP tg and non-tg mice within 24 h after birth and transplanted under the renal capsule of syngeneic  SCID 
mice. 6-8-wk later, the recipients were inoculated  with 10  s PFU-LCMV i.p. and 7 d later their spleens were removed and tested in a 5-6-h slCr- 
release assay for specific CTL activity  against LCMV- and LCMV-NP-infected  targets (see footnotes to Tables 1 and 2). 
In contrast, no additional responses were generated in H-2  b 
mice. CTL responses  of both the H-2  b and H-2  a tg mice 
were effective and efficient in controlling LCMV infection. 
The  CTL  response  to  LCMV  of H-2  b and H-2 d mice 
maps to genes (NP or GP) encoded by the S-RNA (16, 27-32). 
The CTL response in H-2  b mice maps to both GP (aa 33-41 
and aa 276-286) and NP (aa 396-404) proteins, whereas in 
H-2  d mice  the  CTL response  maps  only to  a  single im- 
munodominant NP epitope, aa 118-127  (15, 28).  Here we 
show that expression of NP in the thymus of H-2  b mice 
completely aborts the NP CTL response, but retains the CTL 
response to LCMV-GP. The complete removal (negative se- 
lection) of H-2b-restricted CTL was directly associated with 
a high-affinity interaction of H-2  b NP CTL with MHC class 
I plus peptide. In CTL end point titrations (Fig. 5) this pep- 
tide was effective at a concentration of 10-13 M. In contrast, 
expression of the NP transgene in H-2  a mice resulted in par- 
tial negative selection of CTL to NP. High-affinity  NP-reactive 
CTL were removed, but not lower-affinity  CTL to the same 
epitope. In contrast to the H-2  b NP peptide, the H-2 a NP 
peptide requires a 10,000-fold higher concentration to sensi- 
tize syngeneic target cells for CTL lysis (Fig. 5). 
Thymic and peripheral  Thyl.2-positive LCMV-NP-ex- 
pressing T cells cannot be lysed by LCMV-NP-specific CTL 
in vivo or in vitro. Evidence for this is derived from finding 
nonaltered numbers of CD4 and CD8 cells as determined 
by FACS  |  (Von Herrath, M.G., unpublished experiments) 
in Thyl.2 tg mice before and after infection with LCMV. 
Further, SlCr-labeled  thymic cells or PBL from Thyl.2 tg 
mice cannot be lysed by LCMV-NP-specific CTL in vitro 
(data not shown). The reason(s) why these cells resist CTL- 
mediated lysis is not clear. However, these observations strongly 
suggest that the avidity threshold (peptide density?) between 
T cell and APC required for negative selection in the thymus 
is less than that required for recognition and/or triggering 
of activated  CTL (4, 9).  As shown by thymus transfer ex- 
periments (Table 5), this negative selection  of high-affinity 
cells is due to events taking place in the thymus rather than 
effects of peripheral Thyl.2-positive T  cells expressing  the 
NP protein. 
The repertoire of T  cells is selected in the thymus when 
T  lymphocytes come in contact with MHC class I and II 
molecules plus peptide (1, 3, 6, 33). We show here that MHC 
class I haplotypes, because of different peptide/MHC/TCR 
complex affinities, may vary in terms of the completeness of 
the negative selection process. This observation may explain, 
in part, the differing susceptibilities and incidences of autoim- 
mune diseases among different MHC haplotypes (34, 35) as 
well as the presence of low-affinity T lymphocytes (13, 36) 
in certain autoimmune responses.  Our experimental results 
in a virus infection model agree with those of other investi- 
gators (3-5, 7, 8), who have correlated quantitation of thymic 
selection with MHC class I peptide binding affinity in non- 
viral  systems. 
Our  H-2 a  tg  Thyl.2-NP  generated  a  new  I.CMV- 
GP-specific  CTL response,  perhaps to compensate for the 
removal of the high-affinity  NP-CTL. Although the mecha- 
nism(s)  by which this occurred is uncertain, this switch to 
an alternative La-restricted CTL response indicates its adapt- 
ability and probable hierarchial  control. The H-2  a CTL re- 
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to NP and new GP CTL) is able to control LCMV infection 
in vivo. The number of precursors  for the low-affinity CTL 
to NP in Thyl.2 H-2  a tg mice equaled the numbers found 
for high-affinity NP CTL in non-tg littermates. However, 
these tg H-2  a mice had 50-100-fold fewer GP CTL than 
low-affinity NP-CTL. This probably explains  why the GP 
CTL response was only uncovered after secondary stimula- 
tion but not as a primary CTL response.  Indeed, in >  500 
individual non-tg H-2  a mice, a primary GP-specific CTL re- 
sponse was not present after LCMV challenge (14, 21, and 
our unpublished observations). Possibly, the alternative L a- 
restricted GP response exists but is suppressed  by the im- 
munodominant high-affinity NP response in non-tg mice. 
However, when the immunodominant H-2  a NP CTL re- 
sponse is diminished, hierarchial control of the NP epitope 
is broken, GP-specific CTL occur, and can be cloned by lim- 
iting dilution (yon Herrath, M. G., H. Lewicki, and M. B. A. 
Oldstone, unpublished results).  A hierarchy of factors  that 
control MHC genes in the generation of antiviral CTL re- 
sponses  has been noted elsewhere  (35,  37).  For example, 
H-2L  a is the sole MHC haplotype in normal BALB/c mice 
(KdldDaL  d) for generating a CTL response to influenza virus 
(35).  However,  in  the  absence  of this  L  a haplotype,  the 
H-2K  a serves to restrict the CTL response.  Similar observa- 
tions have been made with LCMV (38). 
The work presented here shows the adaptability of an anti- 
viral CTL response in two given MHC environments. In 
H-2  b mice, thymic expression  of viral NP causes complete 
negative selection of high-avidity NP  CTL but  the anti- 
LCMV-GP CTL response remains unaffected. In H-2  a mice, 
NP CTL of lower avidity are not deleted, pass to the pe- 
riphery, and can be activated. Additionally, a new CTL re- 
sponse to an alternative viral epitope on LCMV-GP is gener- 
ated, which is restricted by the same MHC allele. In both 
scenarios, however, the altered CTL responses suffice to clear 
viral infection in vivo. These in vivo findings in mice under- 
going infection with a natural viral pathogen suggest that 
negative selection is only complete if the affinity between 
TCR and MHC/peptide complex is high and support the 
recently proposed affinity model for thymic selection (7, 8). 
Finally, our findings with LCMV are likely to be pertinent 
in understanding the presence or absence of CTL responses, 
MHC control, and different autoimmune phenotypes observed 
in humans infected in utero or at birth with hepatitis B virus, 
HIV, or cytomegalovirus. 
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